Anixa Biosciences Earns Patent for CAR-T Cancer Therapy
The U.S. Patent and Trademark Office granted San Jose, California biotech firm Anixa Biosciences a patent for its CAR-T technology for treating ovarian cancer.
The patent, titled “Methods and Compositions for Treating Cancer,” is the company’s first for its CAR-T oncology treatment.
The technology “takes advantage of specific hormone-hormone receptor biology to address malignancies and may hold promise to be the one of the first successful CAR-T therapies against solid tumors,” said Anixa chairman, president and CEO Amit Kumar.
Kumar said the technology protected by the patent is broad and could also be used to treat other solid tumors.